FIGURE 4 from Molecular Landscape and Clinical Implication of CCNE1-amplified Esophagogastric Cancer

rwOS in patients with CCNE1-amplified gastric adenocarcinoma. OS (calculated from tissue collection to last day of contact) of CCNE1-amplified versus nonamplified gastric adenocarcinoma (A). Comparison of survival of CCNE1-amplified versus nonamplified gastric adenocarcinoma treated with oxaliplatin (calculated from start of treatment to last day of contact; B). Comparison of survival of CCNE1-amplified versus nonamplified gastric adenocarcinoma treated with trastuzumab (C). Comparison of survival of CCNE1-amplified versus nonamplified HER2-positive gastric adenocarcinoma (by IHC) treated with trastuzumab (D). Comparison of survival of CCNE1-amplified versus nonamplified HER2-positive gastric adenocarcinoma (by ERBB2 CNA analysis) treated with trastuzumab (E). Comparison of survival of CCNE1-amplified versus nonamplified gastric adenocarcinoma treated with immunotherapy with a PD1 or PD-L1 inhibitor (F).